Loading...
XNASAFMD
Market cap18mUSD
Dec 23, Last price  
1.19USD
1D
0.00%
1Q
-64.90%
Jan 2017
-93.39%
IPO
-98.14%
Name

Affimed NV

Chart & Performance

D1W1MN
XNAS:AFMD chart
P/E
—
P/S
2.10
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.81%
Rev. gr., 5y
-19.00%
Revenues
8m
-79.99%
1,173,0005,087,0003,382,0007,562,0006,314,0002,010,00023,735,00021,391,00028,360,00040,366,00041,353,0008,275,000
Net income
-106m
L+23.18%
-14,314,000-26,099,000-259,000-20,239,000-32,216,000-30,223,000-19,477,000-32,365,000-41,366,000-57,523,000-86,004,000-105,938,000
CFO
-110m
L+5.13%
-8,645,000-5,678,000-10,547,000-18,535,000-32,127,000-25,549,00049,438,000-29,056,000-19,400,000-86,591,000-104,892,000-110,269,000

Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
URL
https://www.affimed.com/
IPO date
Sep 12, 2014
Employees
219
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,275
-79.99%
41,353
2.45%
40,366
42.33%
Cost of revenue
119,633
130,889
105,706
Unusual Expense (Income)
NOPBT
(111,358)
(89,536)
(65,340)
NOPBT Margin
Operating Taxes
3
2
2
Tax Rate
NOPAT
(111,361)
(89,538)
(65,342)
Net income
(105,938)
23.18%
(86,004)
49.51%
(57,523)
39.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
235
95,907
124,460
BB yield
-0.25%
-54.33%
-18.87%
Debt
Debt current
6,372
6,326
1,263
Long-term debt
20,178
12,435
18,479
Deferred revenue
464
1,083
7,209
Other long-term liabilities
24,637
Net debt
(46,348)
(171,525)
(190,236)
Cash flow
Cash from operating activities
(110,269)
(104,892)
(86,591)
CAPEX
(3,729)
(696)
(3,850)
Cash from investing activities
(36,059)
5,605
(3,850)
Cash from financing activities
(6,220)
88,557
133,581
FCF
(119,921)
(89,136)
(66,962)
Balance
Cash
72,898
190,286
197,630
Long term investments
12,348
Excess cash
72,484
188,218
207,960
Stockholders' equity
57,807
152,915
135,951
Invested Capital
19,815
43,909
25,900
ROIC
ROCE
EV
Common stock shares outstanding
14,940
14,236
11,950
Price
6.25
-49.60%
12.40
-77.54%
55.20
-5.15%
Market cap
93,374
-47.11%
176,529
-73.24%
659,653
35.79%
EV
47,026
5,004
469,417
EBITDA
(109,609)
(86,637)
(64,006)
EV/EBITDA
Interest
1,806
1,630
712
Interest/NOPBT